KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$237.5 million.

  • Travere Therapeutics' Free Cash Flow rose 133.35% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.8 million, marking a year-over-year increase of 77.93%. This contributed to the annual value of -$237.5 million for FY2024, which is 27.16% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Free Cash Flow is -$237.5 million, which was up 27.16% from -$326.0 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Free Cash Flow peaked at -$49.5 million during FY2020, and registered a low of -$326.0 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$274.8 million, with a median of -$261.0 million in 2022.
  • In the last 5 years, Travere Therapeutics' Free Cash Flow crashed by 220.92% in 2022 and then climbed by 27.16% in 2024.
  • Yearly analysis of 5 years shows Travere Therapeutics' Free Cash Flow stood at -$49.5 million in 2020, then tumbled by 64.29% to -$81.3 million in 2021, then tumbled by 220.92% to -$261.0 million in 2022, then dropped by 24.90% to -$326.0 million in 2023, then increased by 27.16% to -$237.5 million in 2024.